SITC 2021
Yevgeniy R. Semenov, MD, on Cutaneous Immune-Related Adverse Events and Response to Immune Checkpoint Inhibitors
Yevgeniy R. Semenov, MD, of Massachusetts General Hospital and Harvard Medical School, discusses new findings suggesting cutaneous adverse events such as vitiligo, lichenoid dermatitis, and psoriasis—...
Mehmet Altan, MD, on Solid Tumors: Interim Safety and Efficacy Results on NKTR-255 Plus Cetuximab
Mehmet Altan, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a phase Ib dose-escalation study, which showed early evidence of activity for NKTR-255, an investigation...
Lynda Chin, MD, on the Landscape and Future of Digital Medicine
Lynda Chin, MD, of the University of Texas, Austin Dell Medical School and Apricity Health, discusses precision medicine, barriers to its progress, and the challenges that must be met to facilitate be...
Patrick Hwu, MD, and Mary Dean, JD, CAE, on What’s Ahead for Cancer Immunology and SITC
Patrick Hwu, MD, of Moffitt Cancer Center and President of the Society for Immunotherapy of Cancer (SITC), and Mary Dean, JD, CAE, SITC Executive Director, discuss the organization’s mission, strides ...
Sean Khozin, MD, MPH, on Delivering Precision Cancer Care in the Era of Digital Medicine
Sean Khozin, MD, MPH, of CancerLinQ, discusses the therapeutic advances that have made cancer care more targeted, even as real-world patient outcomes lag behind those reported in clinical trials. Dr. ...
Jeffrey Weber, MD, PhD, on Coronavirus, Cancer, and Immunotherapy: Navigating Clinical Trials and Treatment
Jeffrey Weber, MD, PhD, of NYU Langone Medical Center, offers his perspective on the impact of the COVID-19 pandemic on oncology care and cancer clinical trials, as clinicians strive to provide optima...
Vidutolimad Plus Pembrolizumab in PD-1 Refractory Melanoma
The addition of vidutolimod to pembrolizumab could help overcome resistance to immune checkpoint inhibition in patients with metastatic or unresectable cutaneous melanoma, according to data presented ...
Sotigalimab Plus Nivolumab in Anti–PD-1/PD-L1–Refractory Melanoma
Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, but a significant number of patients still fail to respond to anti–PD-1 therapy. The novel combination of sotigal...
Study Examines Safety and Efficacy of Retifanlimab in Recurrent MSI-H/dMMR Endometrial Cancer
The novel PD-1 inhibitor retifanlimab appears to be safe and effective in patients with pretreated, recurrent microsatellite instability–high (MSI-H) or deficient mismatch repair (dMMR) endometrial ca...
Novel Vaccine Platform Plus Pembrolizumab May Boost Immune Response in Advanced HCC
A novel vaccine platform administered in combination with pembrolizumab appears to be safe and effective in patients with advanced hepatocellular carcinoma (HCC), according to data presented by Mark Y...
John M. Kirkwood, MD, on Melanoma: Early Study Results on Vidutolimod and Pembrolizumab
John M. Kirkwood, MD, of the University of Pittsburgh Medical Center, discusses phase Ib findings on the combination of vidutolimod plus pembrolizumab, as well as vidutolimod monotherapy, both of whic...
Hannah E. Dzimitrowicz, MD, on COVID-19 Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors
Hannah E. Dzimitrowicz, MD, of Duke Cancer Center, discusses study results showing that in patients with melanoma and renal cell cancer receiving immune checkpoint inhibitor therapy, the COVID-19 vacc...
Hans Wildiers, MD, on Metastatic Breast Cancer: Comparing Addition of Eftilagimod Alpha vs Placebo to Paclitaxel
Hans Wildiers, MD, of University Hospitals Leuven, discusses the final results from the phase IIb AIPAC study, which suggested that eftilagimod added to paclitaxel may be of benefit to patients older ...
Yuki Muroyama, MD, PhD, on A Novel Marker of Clinical Response to PD-1 Blockade Under Study
Yuki Muroyama, MD, PhD, of the University of Pennsylvania Perelman School of Medicine, discusses the interaction between the immune system and a novel marker—T-cell DNA damage and repair response—to u...
Immunomodulatory Effects of Neoadjuvant Nivolumab, Chemotherapy in NSCLC
The immunomodulatory effects of neoadjuvant immune-based treatments for non–small cell lung cancer (NSCLC) are becoming clearer, in part due to data presented by Schmidt et al at the Society for Immun...
Neoadjuvant Chemoradiation Plus Pembrolizumab Shows No Effect on Tumor-Infiltrating Lymphocytes in Pancreatic Cancer
The addition of the checkpoint inhibitor pembrolizumab to neoadjuvant chemoradiation has failed to overcome the immunosuppressive microenvironment of pancreatic cancer, according to data presented by...
Eftilagimod Alpha Plus Paclitaxel May Improve Survival in HR-Positive, HER2-Negative Metastatic Breast Cancer: AIPAC Trial
The addition of the LAG-3 protein eftilagimod alpha to paclitaxel led to a significant improvement in overall survival in younger patients with hormone receptor (HR)-positive, HER2-negative metastatic...
Phase I Trial Investigates HER-Targeted CAR-M for HER2-Overexpressing Solid Tumors
HER2-targeted chimeric antigen receptor macrophages (CAR-M) could be the next cell therapies to treat advanced solid tumors overexpressing HER2, according to data presented by Kim A. Reiss, MD, and co...
Emily Z. Keung, MD, on Interactions of Sarcoma, Immune Infiltrates, and Checkpoint Blockade
Emily Z. Keung, MD, of The University of Texas MD Anderson Cancer Center, discusses the complex interactions of immune infiltrates and neoadjuvant immune checkpoint blockade (ICB) in patients with res...
Kim A. Reiss, MD, on HER2-Overexpressing Solid Tumors: First-in-Human Study of Anti-HER2 CAR Macrophages
Kim A. Reiss, MD, of the University of Pennsylvania, discusses results of a phase I trial of a CAR-M engineered macrophage cancer therapy, known as CT-0508, for patients with solid tumors that overexp...
Stephanie T. Schmidt, PhD, on NSCLC: The Immunomodulatory Impact of Neoadjuvant Chemotherapy and Immune-Based Treatments
Stephanie T. Schmidt, PhD, of The University of Texas MD Anderson Cancer Center, discusses the first integrated examination of the immunomodulatory effects of neoadjuvant chemotherapy, nivolumab, and ...
